当前位置: 首页 > 期刊 > 《医药产业资讯》 > 2016年第24期 > 正文
编号:12954091
普拉睾酮的临床研究进展(7)
http://www.100md.com 2016年8月25日 《中国医药导报》2016年第24期
     [30] Shufelt C,Bretsky P,Almeida CM,et al. DHEA-S levels and cardiovascular disease mortality in postmenopausal women: results from the National Institutes of Health: National Heart, Lung, and Blood Institute (NHLBI)-sponsored Women’s Ischemia Syndrome Evaluation (WISE) [J]. J Clin Endocrinol Metab,2010,95:4985-4992.

    [31] Wenzel SE,Robinson CB,Leonard JM,et al. Nebulized dehydroepiandrosterone-3-sulfate improves asthma control in the moderate-to-severe asthma results of a 6-week,randomized,double-blind,placebo-controlled study [J]. Allergy Asthma Proc,2010,31:461-471.

    [32] Tabata N,Tagami H,Terui T. Dehydroepiandrosterone may be one of the regulators of cytokine production in atopic dermatitis [J]. Arch Dermatol Res,1997,289:410-414.

    [33] Kasperska-Zajac A,Brzoza Z,Rogala B. Lower serum concentration of dehydroepiandrosterone sulphate in patients suffering from chronic idiopathic urticaria [J]. Allergy,2006;61:1489-1490.

    [34] Kasperska-Zajac A,Brzoza Z,Rogala B. Serum concentration of dehydroepiandrosterone sulphate in female patients with chronic idiopathic urticaria [J]. J Dermatol Sci,2006,41:80-81. (夏军 覃金玲 丁明和 严常开)
上一页1 2 3 4 5 6 7